Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cost-Effectiveness Analysis
100%
Randomized Controlled Trial
89%
Health Care Cost
55%
Treatment Resistant Depression
55%
Quetiapine
55%
Diseases
36%
Mental Health
30%
Esophageal Varices
27%
Beta Adrenergic Receptor Blocking Agent
27%
Placebo
27%
Child Parent Relation
27%
Early Intervention in Psychosis
27%
Mixed Methods
27%
Mental Health Service
27%
Low and Middle Income Countries
27%
Carvedilol
23%
Liver Cirrhosis
23%
Arm
17%
National Health Service
16%
Bipolar Disorder
11%
Depressive Disorder
11%
Clinician
11%
Quality of Life
10%
Liver Disease
9%
Portal Hypertension
9%
Bleeding
9%
Hepatic Encephalopathy
9%
Decompensated Liver Cirrhosis
9%
Ascites
9%
Clinical Examination
9%
Adverse Event
8%
Antidepressant
8%
COVID-19
6%
Health Status
6%
Hamilton Rating Scale for Depression
5%
DSM-5
5%
Symptomatology
5%
Major Depressive Episode
5%
Nursing and Health Professions
Mental Health
50%
Cost Effectiveness Analysis
39%
Treatment Resistant Depression
27%
Quetiapine
27%
Early Intervention
27%
Feasibility Study
27%
Mental Health Service
27%
Clinical Skill
27%
Health Practitioner
27%
Clinical Examination
13%
Diseases
13%
Health Care
9%
Randomization
8%
Socialized Medicine
8%
Antidepressant
8%
Health Care Cost
6%
Health Status
6%
COVID-19
6%
Confidence Interval
5%
Depressive Disorder
5%
Psychology
Mental Health
95%
Mental Health Service
34%
Mixed Methods
31%
Early Intervention
27%
Bipolar Disorder
13%
Mental Health Problem
13%
MHealth
13%
Healthcare
11%
Quality of Life
9%
Mental Health Promotion
6%
Behavioral Disorder
6%
Mood
6%
COVID-19
6%
Therapeutic Alliance
6%